Genetic Signatures Launches Analyte-Specific Reagents in US; Eyes FDA Approval for MDx Panels | GenomeWeb

NEW YORK (GenomeWeb) – Australian molecular diagnostics manufacturer Genetic Signatures recently launched a line of analyte-specific reagents in the US and collaborated with the University of California, Los Angeles to evaluate a multiplex panel assay for enteric protozoan infections with an eye toward regulatory approval and the US diagnostics market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.